Skip to main content

Table 2 Treatment prior to lenvatinib therapy

From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

  LEN monotherapy LEN combination
First-line treatment 27/69% 62/86%
Second-line treatment 12/31% 8/11%
 Sorafenib 12/31% 3/4%
 Apatinib 0 3/4%
 PD-1 antibody 0 2/3%
Third-line treatment 0 2/3%
  1. Data are presented as n/%
  2. LEN, lenvatinib; PD-1, programmed cell death protein-1